EUROPE DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The market is segmented by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by Segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors), and by Geography.

Market Snapshot

European Diabetes Drug Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: 0 %
European Diabetes Drug Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • The European diabetes drug market is expected to record a high CAGR of 5.68% during the forecast period (2019 - 2024) due to the growing prevalence of diabetes, growing geriatric population levels, unhealthy diet, and increasing levels of physical inactivity.
  • Diabetes is becoming an increasingly common health condition, which can disable patients and potentially lead to fatal health complications.
  • Europe's diabetes spending is approx. 9% of the total global healthcare expenditure; expenditure on diabetes largely varies among countries in Europe. It ranges from EUR 312 per-capita in the Republic of Macedonia to EUR 6,896 per-capita in Norway.
  • Similarly, prevalence is also widely varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular diseases, blindness, kidney failure, and lower limb amputation.
  • Currently, 30 countries out of 47 are implementing a national plan that includes diabetes individually or within a plan for non-communicable diseases (NCDs).
  • Another ten have announced such plans for the near future. The remaining seven either have joined an international initiative on diabetes, or adopted a political resolution, or are covering diabetes in their national health plans. An increasing number of countries are moving toward plans for NCDs, rather than plans addressing diabetes alone. However, European countries still have to implement a fully comprehensive, multi-sectoral approach to diabetes, including factors from outside the health sector within their diabetes policies.

Scope of the Report

The market is segmented by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by Segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors), and by Geography.

By Drug
Oral Anti-diabetic Drugs
Biguanide (Value and Volume 2012-2024)
Metformin
Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha - Glucosidase Inhibitors
Dopamine - D2 Receptor Agonist (Value and Volume 2012-2024)
Bromocriptin (Cycloset)
Sodium - Glucose Cotransport - 2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2024)
Sulfonylureas
Meglitinide (Value and Volume 2012-2024)
Meglitinide
Insulin
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-insulin Injectable Drugs
GLP1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drugs
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
Europe
United Kingdom (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
Germany (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
Italy (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
Spain (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
France (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
Russia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
Rest of Europe (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oral Anti-diabetic Drugs and Insulin hold a Significant Market Share

  • Among the diabetes drugs in the European region, oral anti-diabetic and insulin drugs occupy a significant market share. 
  • Of the insulin drugs, basal insulins subsegment's market size is high due to high market penetration. Insulin glargine is the most widely used drug, and it has quite a few biosimilars in the market. 
  • SGLT-2 inhibitors and DPP-4 inhibitor drugs are expected to gain a significant market share and record a high CAGR of more than 15% during the forecast period.
European Diabetes Drug Market Key Trends

Germany & France Alone Occupy More than 30% of Share in European Diabetes Drugs Market

  • Among the studied countries, Germany is expected to lead the market studied, with a considerable market share of 22%, followed by France.
  • In the GLP-1 segment, Victoza holds the largest market share in the European region, and a similar trend is being observed in Germany as well. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells and suppressing inappropriate elevated glucagon secretion.
  • The German generics market is vast, and the market for oral anti-diabetic drugs is expected to increase during the forecast period. However, pricing is a major issue in Germany, and many companies have backed-up with their plan to launch insulin in the country. 
  • In France, the oral DPP-4 drugs dominate the market, followed by GLP-1 and Insulin. 
European Diabetes Drug Market Growth by Region

Competitive Landscape

  • The market is highly consolidated, with a few significant manufacturers having a global market presence. 
  • Mergers and Acquisitions Among Major Players:
    • The European Commission and Australian regulatory body approved marketing of Biocon, and the Mylan co-developed drug Insulin Glargine Semglee is boosting the demand in the diabetes market.
  • Innovations in the Diabetes Drugs Market:
    • Eli Lilly has submitted an application for Glucagon which can be administered via the nasal route in Europe and the United States if it approved it can be used to treat diabetes.

 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Oral Anti-diabetic Drugs

        1. 5.1.1.1 Biguanide (Value and Volume 2012-2024)

          1. 5.1.1.1.1 Metformin

        2. 5.1.1.2 Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)

          1. 5.1.1.2.1 Alpha - Glucosidase Inhibitors

        3. 5.1.1.3 Dopamine - D2 Receptor Agonist (Value and Volume 2012-2024)

          1. 5.1.1.3.1 Bromocriptin (Cycloset)

        4. 5.1.1.4 Sodium - Glucose Cotransport - 2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)

          1. 5.1.1.4.1 Invokana (Canagliflozin)

          2. 5.1.1.4.2 Jardiance (Empagliflozin)

          3. 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)

          4. 5.1.1.4.4 Suglat (Ipragliflozin)

        5. 5.1.1.5 Dipeptidyl peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

          1. 5.1.1.5.1 Januvia (Sitagliptin)

          2. 5.1.1.5.2 Onglyza (Saxagliptin)

          3. 5.1.1.5.3 Tradjenta (Linagliptin)

          4. 5.1.1.5.4 Vipidia/Nesina (Alogliptin)

          5. 5.1.1.5.5 Galvus (Vildagliptin)

        6. 5.1.1.6 Sulfonylureas (Value and Volume 2012-2024)

          1. 5.1.1.6.1 Sulfonylureas

        7. 5.1.1.7 Meglitinide (Value and Volume 2012-2024)

          1. 5.1.1.7.1 Meglitinide

      2. 5.1.2 Insulin

        1. 5.1.2.1 Basal or Long-acting Insulins

          1. 5.1.2.1.1 Lantus (Insulin Glargine)

          2. 5.1.2.1.2 Levemir (Insulin Detemir)

          3. 5.1.2.1.3 Toujeo (Insulin Glargine)

          4. 5.1.2.1.4 Tresiba (Insulin Degludec)

          5. 5.1.2.1.5 Basaglar (Insulin Glargine)

        2. 5.1.2.2 Bolus or Fast-acting Insulins

          1. 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.2.2.2 Humalog (Insulin Lispro)

          3. 5.1.2.2.3 Apidra (Insulin Glulisine)

        3. 5.1.2.3 Traditional Human Insulins

          1. 5.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.2.3.2 Humilin

          3. 5.1.2.3.3 Insuman

        4. 5.1.2.4 Biosimilar Insulins

          1. 5.1.2.4.1 Insulin Glargine Biosimilars

          2. 5.1.2.4.2 Human Insulin Biosimilars

      3. 5.1.3 Non-insulin Injectable Drugs

        1. 5.1.3.1 GLP1 Receptor Agonists

          1. 5.1.3.1.1 Victoza (Liraglutide)

          2. 5.1.3.1.2 Byetta (Exenatide)

          3. 5.1.3.1.3 Bydureon (Exenatide)

          4. 5.1.3.1.4 Trulicity (Dulaglutide)

          5. 5.1.3.1.5 Lyxumia (Lixisenatide)

        2. 5.1.3.2 Amylin Analogue

          1. 5.1.3.2.1 Symlin (Pramlintide)

      4. 5.1.4 Combination Drugs

        1. 5.1.4.1 Insulin Combinations

          1. 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

        2. 5.1.4.2 Oral Combination

          1. 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

    2. 5.2 Geography

      1. 5.2.1 Europe

        1. 5.2.1.1 United Kingdom (Value and Volume 2012-2024)

          1. 5.2.1.1.1 Oral Anti-diabetic Drugs

          2. 5.2.1.1.2 Insulin

          3. 5.2.1.1.3 Non-insulin Injectable Drugs

          4. 5.2.1.1.4 Combination Drugs

          5. 5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

        2. 5.2.1.2 Germany (Value and Volume 2012-2024)

          1. 5.2.1.2.1 Oral Anti-diabetic Drugs

          2. 5.2.1.2.2 Insulin

          3. 5.2.1.2.3 Non-insulin Injectable Drugs

          4. 5.2.1.2.4 Combination Drugs

          5. 5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

        3. 5.2.1.3 Italy (Value and Volume 2012-2024)

          1. 5.2.1.3.1 Oral Anti-diabetic Drugs

          2. 5.2.1.3.2 Insulin

          3. 5.2.1.3.3 Non-insulin Injectable Drugs

          4. 5.2.1.3.4 Combination Drugs

          5. 5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

        4. 5.2.1.4 Spain (Value and Volume 2012-2024)

          1. 5.2.1.4.1 Oral Anti-diabetic Drugs

          2. 5.2.1.4.2 Insulin

          3. 5.2.1.4.3 Non-insulin Injectable Drugs

          4. 5.2.1.4.4 Combination Drugs

          5. 5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

        5. 5.2.1.5 France (Value and Volume 2012-2024)

          1. 5.2.1.5.1 Oral Anti-diabetic Drugs

          2. 5.2.1.5.2 Insulin

          3. 5.2.1.5.3 Non-insulin Injectable Drugs

          4. 5.2.1.5.4 Combination Drugs

          5. 5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

        6. 5.2.1.6 Russia (Value and Volume 2012-2024)

          1. 5.2.1.6.1 Oral Anti-diabetic Drugs

          2. 5.2.1.6.2 Insulin

          3. 5.2.1.6.3 Non-insulin Injectable Drugs

          4. 5.2.1.6.4 Combination Drugs

          5. 5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

        7. 5.2.1.7 Rest of Europe (Value and Volume 2012-2024)

          1. 5.2.1.7.1 Oral Anti-diabetic Drugs

          2. 5.2.1.7.2 Insulin

          3. 5.2.1.7.3 Non-insulin Injectable Drugs

          4. 5.2.1.7.4 Combination Drugs

          5. 5.2.1.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetic Population (2012-2024)

    2. 6.2 Type-2 Diabetic Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Takeda

      2. 7.1.2 Pfizer

      3. 7.1.3 Eli Lilly

      4. 7.1.4 Janssen Pharmaceuticals

      5. 7.1.5 Astellas

      6. 7.1.6 Boehringer Ingelheim

      7. 7.1.7 Merck and Co.

      8. 7.1.8 AstraZeneca

      9. 7.1.9 Bristol Myers Squibb

      10. 7.1.10 Novartis

      11. 7.1.11 Sanofi

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Europe Diabetes Drugs Market market is studied from 2016 - 2027.

The Europe Diabetes Drugs Market is growing at a CAGR of 0% over the next 5 years.

Eli Lilly, Astrazeneca, Novo Nordisk, Sanofi, Boehringer Ingelheim are the major companies operating in Europe Diabetes Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!